Generic Lo Loestrin Fe Availability
LO LOESTRIN FE (ethinyl estradiol; norethindrone acetate - tablet;oral)
Manufacturer: WARNER CHILCOTT LLC
Approval date: October 21, 2010
Strength(s): 0.01MG,0.01MG;1MG,N/A [RLD]
Has a generic version of Lo Loestrin Fe been approved?
No. There is currently no therapeutically equivalent version of Lo Loestrin Fe available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lo Loestrin Fe. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Issued: September 3, 1996
Inventor(s): Hodgen; Gary D.
Assignee(s): The Medical College of Hampton Roads
A method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.Patent expiration dates:
- July 22, 2014✓
- July 22, 2014
Extended estrogen dosing contraceptive regimen
Issued: April 27, 2010
Inventor(s): Boissonneault; Roger M.
Assignee(s): Warner Chilcott Company, LLC
A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.Patent expiration dates:
- February 2, 2029✓
- February 2, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 21, 2013 -
- Lo Loestrin Fe Consumer Information (Drugs.com)
- Lo Loestrin Fe Consumer Information (Wolters Kluwer)
- Lo Loestrin Fe birth control Consumer Information (Cerner Multum)
- Lo Loestrin Fe Advanced Consumer Information (Micromedex®)
- Loestrin Fe Consumer Information (Wolters Kluwer)
- Microgestin Fe Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol (HRT) Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol chewable tablets Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol tablets Consumer Information (Wolters Kluwer)
- Gildess birth control Consumer Information (Cerner Multum)
- Ethinyl estradiol and norethindrone HRT Consumer Information (Cerner Multum)
- Ethinyl estradiol and norethindrone birth control Consumer Information (Cerner Multum)
- Femhrt Lo Advanced Consumer Information (Micromedex®)
- Larin 1/20 Advanced Consumer Information (Micromedex®)
- Loestrin 1.5/30 Oral Advanced Consumer Information (Micromedex®)
- Ethinyl estradiol and norethindrone Advanced Consumer Information (Micromedex®)
- Norethindrone, ethinyl estradiol, and ferrous fumarate Advanced Consumer Information (Micromedex®)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|